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Introduction
The primate-specific Hpr is a plasma protein with 91% sequence identity to the 1-1 phenotype of Hp, the hemoglobin-binding protein in plasma. Hpr is a core component of a subclass of HDL referred to as trypanosome lytic factor-1 (TLF1) based on its ability to induce lysis of the African parasite trypanosoma T. b. brucei, which primarily infects non-primate mammals. 1, 2 Aside from Hpr, the main TLF1 protein components are apolipoprotein A-I (apoA-I) 3, 4 and the primate-specific apoL-I. 5 Both Hpr and apoL-I have been reported to possess lytic activity. 2, 3, [5] [6] [7] Like Hp, Hpr is synthesized as an ~45 kDa protein that is proteolytically cleaved to form an α-and a β−chain which remain connected via a disulfide bond. However, in contrast to Hp, Hpr lacks a glycosylation site and a cysteine involved in inter-α-chain bonding. 8 Human Hp has either one (Hp1 genotype) or two (Hp2 genotype) of such cysteines leading to the formation of the covalent (αβ) 2 structure (Hp1-1 phenotype) or larger (αβ)−oligomers (Hp2-2 and Hp2-1 phenotypes). 9 Furthermore, the α-chain of Hpr differs from that of Hp by containing the hydrophobic signal peptide, 2,4 which may explain the association of Hpr to lipoprotein particles.
Hp avidly binds hemoglobin released into plasma during physiological and pathological hemolysis thereby preventing heme-mediated oxidative side effects in the kidney and other organs. 10, 11 Formation of the Hp-hemoglobin complex promotes high affinity binding to the monocyte/macrophage-specific scavenger receptor CD163 which mediates internalization of the complex. 12 In contrast, immunoprecipitation experiments with TLF1 have suggested that Hpr is inactive in terms of hemoglobin binding. 13, 14 Due to the high degree of sequence similarity between
Hp and Hpr we have investigated the hemoglobin-and receptor-binding potential of Hpr using a direct molecular approach.
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Study design Expression and purification of recombinant Hp1-1 and Hpr
Hp1 cDNA was amplified from a human foetal liver cDNA library (Clontech, Palo Alto, CA) and ligated into the pcDNA5/FRT vector (Invitrogen, Taastrup, Denmark). A construct encoding Hpr was generated by multiple rounds of site-directed mutagenesis (Quick change, Invitrogen). Flp-In 293 cells (Invitrogen) were transfected using FuGENE 6 (Roche Diagnostics, Hvidovre, Denmark) and stable transfectants selected using 150 µg/ml hygromycin B (Invitrogen). Serum-free 293 SFM II medium (Invitrogen) was collected from expression cultures and subjected to hemoglobin A 0 (Sigma, Brøndby, Denmark)-affinity chromatography essentially as described. 15 For amino-terminal sequencing, the purified proteins were heated in SDS-PAGE sample buffer for 3 min at 80 °C, separated by SDS-gel electrophoresis, and subsequently transferred to a polyvinylidene difluoride membrane as described. 16 
Surface Plasmon Resonance (SPR) analysis
SPR analysis was performed on a Biacore 3000 instrument (Biacore, Sweden) as described. (DAKOCytomation, Glostrup, Denmark)) and amino-terminal sequencing/mass spectrometry essentially as described. 19 The concentration of Hp was determined by ELISA using biotinylated anti-human Hp (DAKOCytomation).
Quantification of Hpr levels
Immunostained Hpr was visualized by using the ECL Western blot detection system (Amersham Biosciences, Hillerød, Denmark) and a FUJIFILM LAS-1000 luminescence image analyzer.
Quantification relatively to standards of recombinant Hpr was performed by using the MultiGauge 3.0 software. The concentration of recombinant Hpr was determined by protein hydrolysis and amino acid analysis.
Results and discussion
Hpr and Hp (1-1 phenotype) were expressed as recombinant proteins in a mammalian 293 cell expression system. Binding of hemoglobin to Hpr was indicated by the surprising observation that hemoglobin-affinity chromatography was applicable for purification of both expression products. In agreement with the findings on the authentic proteins, 13 non-reducing denaturing gel electrophoresis of the recombinant proteins showed migration of Hpr and Hp corresponding to ∼45 kDa and ∼110 kDa proteins, respectively (Fig. 1A) . However, non-denaturing S-200 gel filtration 18 showed identical elution of Hpr and Hp1-1 (data not shown), indicating that Hpr non-covalently also associates into a dimeric (αβ) 2 structure.
SPR analysis showed an almost irreversible and virtually indistinguishable high affinity binding of hemoglobin A 0 to both recombinant proteins (Fig. 1B) . Similar SPR data were obtained for hemoglobin A 0 , hemoglobin A 2 , and hemoglobin S (data not shown). Hpr efficiently competed for binding of Hp to hemoglobin and vice versa (Fig. 1C) . The signal peptide of the recombinant Hpr α-chain was found to be removed in contrast to that of plasma-derived Hpr. 2, 4 However, since hemoglobin is known to bind to the β-chain of Hp [20] [21] [22] it seems unlikely that this difference affects hemoglobin binding to Hpr.
In contrast to the similar hemoglobin-binding properties, Hpr and Hp in complex with hemoglobin showed a significant difference in binding to CD163 (Fig. 1D) . Whereas the Hphemoglobin complex formation induced a considerable increase in binding to CD163 relative to hemoglobin alone, 12,23 such effect was not apparent for the Hpr-hemoglobin complex (Fig. 1D) .
Accordingly, SPR analysis showed no interference of Hpr with Hp-hemoglobin binding to CD163
(data not shown).
To show hemoglobin-binding activity of native Hpr in plasma, we identified human plasma proteins precipitated by hemoglobin-Sepharose. Immunoblotting and mass spectrometry/aminoFor personal use only. on December 24, 2017. by guest www.bloodjournal.org From terminal sequencing (Fig. 2) identified Hp in multiple sizes and Hpr (containing the signal peptide) in a 45 kDa monomeric and a 90 kDa form. The 90 kDa form is in agreement with previous data reporting an SDS-resistant dimeric form of Hpr. 13 Reducing SDS-PAGE and subsequent immunoblotting of hemoglobin affinity-purified proteins from the Hp2-1 serum displayed in Fig.   2A showed the characteristic difference in migration of the α-subunits specific for Hp1, Hp2 and Hpr 13 (Fig. 2B) . The staining intensities of these bands comply with the measured plasma The present data explains the previous observation 13 that two patients with severe hemolysis, due to paroxysmal nocturnal hemoglobinuria, had depletion of ∼98% of the Hp pool in plasma but virtually normal levels of Hpr. However, this observation is likely not due to lack of binding of Hpr to hemoglobin as originally suggested, 13 but may be a consequence of the pronounced difference in CD163 binding of Hpr-hemoglobin and Hp-hemoglobin. Furthermore, our data suggest that the hemoglobin previously reported to be present in TLF1 particles 2, 13 is not a contaminant but represents Hpr-bound hemoglobin.
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The absent induction of high affinity binding to CD163 when hemoglobin binds to Hpr indicates that some of the differences in the primary structure of Hp versus Hpr are essential for receptor binding. Furthermore, the very low affinity for CD163 and the association with high molecular weight particles resisting renal clearance, suggest an extended circulation time of Hpr-bound hemoglobin relative to free and Hp-associated hemoglobin. Although a previous study 13 of hemoglobin-exposed TLF1 particles did not reveal increased trypanosoma-lytic activity, it is intriguing to speculate that the oxidative potential of Hpr-bound hemoglobin may be a part of the innate immune defense as originally proposed. 2 Moreover, it could be speculated that association of Hpr-bound hemoglobin with the anti-oxidant apoA-I 24, 25 in plasma may protect the circulatory system from the oxidative properties of hemoglobin which may be uncovered subsequent to internalization by T. b. brucei.
Non-immune biological activity of circulating hemoglobin bound to HDL particles should also be considered. Hemoglobin released into plasma or added to plasma as a blood substitute scavenges NO, and this is associated with smooth muscle dystonias, endothelial dysfunction, and thrombosis. 26, 27 It will be highly important to investigate whether this toxicity of hemoglobin is influenced by circulating plasma Hpr/HDL.
Finally, the presence of two hemoglobin-binding haptoglobins in plasma instead of one has to be taken into account when measuring haptoglobin and 'free' hemoglobin in plasma, particularly in patients with low Hp levels where Hpr becomes a prominent hemoglobin-binding protein. SDS-polyacrylamide gel of Hp1-1 purified from human plasma, Hp2-2 purified from human plasma, and purified recombinant Hpr, respectively, demonstrating the distinct migration patterns of the Hp1, Hp2 and Hpr α-chains. The identity of the bands from the purified proteins was verified by mass spectrometry (data not shown). C, Silver-stained 8-16% SDS-polyacrylamide gel of proteins from normal human serum bound to hemoglobin-coupled Sepharose or underivatized Sepharose.
Figure legends
The identity of the protein bands representing apoL-I and Hpr was determined by mass spectrometry and amino-terminal sequencing (as indicated).
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